Nektar TherapeuticsNKTRNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Latest
-2.96%
↓ 1245% vs avg
Percentile
P29
Within normal range
Streak
1 yr
Consecutive declineDecelerating
Average
0.26%
Historical baseline
PeriodValue
2025-2.96%
20245.91%
2023-47.71%
2022-45.46%
2021-2.06%
2020-5.96%
20198.77%
201848.82%
201731.73%
201611.50%